For the Inventor, By the Inventor

Enter assignee name

Beijing Tide Pharmaceutical Co., Ltd.

USPTO Granted Patents = 18

EPO Patents = 8

Forward Citations = 20

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Yanping Zhao (17 out of 17 patents)

Hongjun Wang (16 out of 26 patents)

Liying Zhou (16 out of 17 patents)

4. Yuanyuan Jiang (14 out of 14 patents)

5. Yanan Liu (13 out of 17 patents)

6. Jing Li (12 out of 121 patents)

7. Gong Li (10 out of 12 patents)

8. Kai Liu (7 out of 176 patents)

9. Yeming Wang (7 out of 7 patents)

10. Ning Shao (6 out of 8 patents)

11. Fengping Xiao (6 out of 6 patents)

12. Weiting Zhong (5 out of 5 patents)

13. Jianmei Pang (5 out of 5 patents)

14. Huai Huang (5 out of 5 patents)

15. Fajie Li (4 out of 4 patents)

18 patents: Sort by Forward Citations

1. 12509479 - P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof (2025-12-30),

2. 12485108 - Method for treating fatty liver disease and/or steatohepatitis (2025-12-02),

3. 12459917 - Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof (2025-11-04),

4. 12410192 - Compound for inhibiting and inducing degradation of EGFR kinase (2025-09-09),

5. 12398118 - Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof (2025-08-26),

6. 12365665 - Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof (2025-07-22),

7. 12180243 - Receptor inhibitor, pharmaceutical composition comprising same, and use thereof (2024-12-31),

8. 11939578 - Double-stranded RNA molecule targeting CKIP-1 and use thereof (2024-03-26),

9. 11938222 - Pregabalin sustained release composition and method for preparing the same (2024-03-26),

10. 11919918 - P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof (2024-03-05),

11. 11905274 - Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof (2024-02-20),

12. 11453690 - Receptor inhibitor, pharmaceutical composition comprising same, and use thereof (2022-09-27),

13. 11414444 - P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof (2022-08-16),

14. 11390609 - Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof (2022-07-19),

15. 11155819 - Double-stranded RNA molecule targeting CKIP-1 and use thereof (2021-10-26),

Beijing Tide Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company specializing in research, development, and production of high-quality pharmaceutical products. With a focus on innovation and quality, Tide Pharmaceutical is dedicated to improving healthcare and enhancing the well-being of people worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

18 Patents

#151 in Beijing

#1,441 in China

#33,177 in the World

Beijing Tide Pharmaceutical Co., Ltd.

Forward Citations = 20

40 inventors:

Yanping Zhao (17 out of 17 patents)

Hongjun Wang (16 out of 26 patents)

Liying Zhou (16 out of 17 patents)

4. Yuanyuan Jiang (14 out of 14 patents)

5. Yanan Liu (13 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…